Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPP1CC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP1CC Recombinant Protein (Active/Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic assays and SPR selectivity screening. |
View PPP1CC Products |
| Gene Delivery | PPP1CC Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View PPP1CC Products |
| Benchmark Ab | Anti-PPP1CC Recombinant Antibody Recombinant positive control for western blot, IHC, and target engagement assays. |
View PPP1CC Products |
| Validator | PPP1CC siRNA Set For target knockdown verification and phenotypic confirmation. |
View PPP1CC Products |
| Related Target A | PPP1CA Highly homologous isoform. Critical for counter-screening to ensure drug selectivity. |
View PPP1CA Products |
| Related Target B | PPP1CB Highly homologous isoform. Required for establishing pan-PP1 vs isoform-selective profiles. |
View PPP1CB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PPP1CA/B/C) | Full panel of human PPP1CA, PPP1CB, and PPP1CC recombinant proteins strictly verified by Mass Spectrometry. |
| Intracellular Target Validation | High-titer Lentivirus particles and validated siRNA sets for precise modulation of PPP1CC expression in cell-based functional assays. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included for target engagement and localization studies. |
| False Positives in Small Molecule Screens | High-purity, low-endotoxin proteins ensure reliable biophysical (SPR/DST) binding assays without non-specific aggregation. |
Live PPP1CC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PPP1CC therapeutics is intensifying, with major players shifting focus from traditional global phosphatase inhibitors to isoform-selective small molecules and PROTACs (Proteolysis Targeting Chimeras). As first-generation therapies targeting protein-protein interactions (PPIs) between PP1 catalytic and regulatory subunits reach the clinic, the next wave of R&D is targeting the specific catalytic subunit PPP1CC to modulate cell cycle progression, particularly in refractory solid tumors and hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Prostate Cancer, Colorectal Cancer | Enzymatic activity assays and SPR binding comparison (Need Mutant vs WT Proteins) |
| PROTAC (Degrader) | Targeted Protein Degradation (TPD) Pioneers | Oncology, Neurodegenerative Diseases | Intracellular degradation kinetics (Need Lentivirus for Stable Cell Lines & siRNA validation) |
| Peptide Therapeutics | Specialized Biotech Firms | Male Contraception, Metabolic Disorders | Binding affinity profiling (Need high-purity recombinant PPP1CC ECD-equivalent domains) |